Seaport Therapeutics' IPO

Listed May 1, 2026 at $18 on Nasdaq as SPTX.

Offer price
$18
Market cap
$955M
Shares
14,160,000

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed May 1, 2026.

What does Seaport Therapeutics do?

“We are a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.”
From its final prospectus (424B4), filed May 1, 2026
Seaport Therapeutics' facts, each with its source
FactSeaport
Therapeutics
Founded2002From its final prospectus (424B4) of May 1, 2026
HeadquartersBoston, MassachusettsFrom its final prospectus (424B4) of May 1, 2026
Employees58 full-time, as of April 1, 2026From its final prospectus (424B4) of May 1, 2026
Websiteseaporttx.comFrom its final prospectus (424B4) of May 1, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Seaport Therapeutics' facts, each with its source
FactSeaport
Therapeutics
Shares offered14,160,000From the final prospectus (424B4) filed May 1, 2026
Offer price$18 a shareFrom the final prospectus (424B4) filed May 1, 2026
Raised at that price$255 millionFrom the final prospectus (424B4) filed May 1, 2026
Underwriters' discount$17.8 millionFrom the final prospectus (424B4) filed May 1, 2026
Underwriters' option2,124,000 more sharesFrom the final prospectus (424B4) filed May 1, 2026
UnderwritersGoldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and StifelFrom the final prospectus (424B4) filed May 1, 2026, as its cover names them
ExchangeNasdaq Global Select Market, as SPTXFrom the final prospectus (424B4) filed May 1, 2026
Shares outstanding after53,027,817From the final prospectus (424B4) filed May 1, 2026
Market cap at the offer price$955 millionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

Seaport Therapeutics' facts, each with its source
FactSeaport
Therapeutics
Net loss$74.9 million, year to December 31, 2025From its final prospectus (424B4) of May 1, 2026, its summary financial data
Last preferred stockSeries B preferredFrom its final prospectus (424B4) of May 1, 2026

What risks does Seaport Therapeutics name first?

  1. “We are a clinical-stage therapeutics company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability.”
  2. “Even if this offering is successful, we will require additional funding in order to finance operations.”
  3. “Our business is highly dependent on the success of our product candidates, particularly GlyphAllo for the treatment of MDD with or without anxious distress and GlyphAgo for the treatment of generalized anxiety disorder, or GAD, and MDD. If we are unable to successfully complete clinical development…”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of Seaport Therapeutics' IPO

Seaport Therapeutics' IPO dates, each with its source
WhatDay
Registration filedForm S-1, SEC EDGARApr 10, 2026
Exchange registration filedexchange registration (Form 8-A), SEC EDGARApr 28, 2026
Declared effective by the SECSEC notice of effectiveness, SEC EDGARApr 30, 2026
Pricedfinal prospectus (424B4), filed May 1, SEC EDGARApr 30, 2026
First tradeMassive's IPO calendarMay 1, 2026
Lock-up endsfinal prospectus, SEC EDGAR: “”Oct 27, 2026

How did its first days trade?

From its daily bars, each close against its $18 offer price.

Seaport Therapeutics' first sessions
DayOpenCloseFrom the
offer
May 1$21$19.84+10.2%
May 4$19.17$17-5.6%
May 5$17.35$16-11.1%
May 6$16.01$16-11.1%
May 7$16.05$15.50-13.9%

The other IPOs expected

The other IPOs expected or in registration
CompanyPrice

Seaport Therapeutics IPO questions

When is Seaport Therapeutics' IPO?

Listed May 1, 2026 at $18 on Nasdaq as SPTX.

What is Seaport Therapeutics' IPO price?

Seaport Therapeutics' IPO priced at $18 a share, per its final prospectus of May 1, 2026.

How many shares is Seaport Therapeutics selling?

14,160,000 shares, and the underwriters may buy 2,124,000 more, per its final prospectus (424B4).

Who are the underwriters?

Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and Stifel, as the prospectus's cover names them.

When does the lock-up end?

Seaport Therapeutics' IPO lock-⁠up ends Oct 27, 2026. Its final prospectus says: “.”

Does Breakaway rate Seaport Therapeutics?

Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.

Can Breakaway say where Seaport Therapeutics' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

  • Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
  • The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
  • The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
  • The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
  • Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and May 2026's listings.

Sources: Seaport Therapeutics, Inc.'s final prospectus (424B4) of May 1, 2026; the prices, the stock's daily bars, 15 minutes behind.

Not advice. Figures from each company's SEC filings, linked on each line. Breakaway is not an underwriter, broker, or adviser, and does not say where a price will go.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs; recorded live since Sep 9 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.